Trial Profile
A Prospective, Open-Label, Multicenter, Single-Arm, Interventional Study to Evaluate the Efficacy and Tolerability of Once-Daily Oros Hydromorphone for Cancer Pain Treatment in Korean Cancer Patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Mar 2013
Price :
$35
*
At a glance
- Drugs Hydromorphone (Primary)
- Indications Cancer pain
- Focus Therapeutic Use
- Sponsors Janssen
- 17 Dec 2012 Actual initiation date changed from Nov 2011 to Dec 2011 as reported by ClinicalTrials.gov.
- 01 Sep 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jun 2012 New trial record